New hope for Hard-to-Treat prostate cancer? early trial launches
Disease control
Recruiting now
This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…
Phase: PHASE1, PHASE2 • Sponsor: Pathos AI, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC